University Hospital of Bern, Inselspital
Bern, 3010, Switzerland
NCT Number: NCT05037526
Once a pregnant mother is diagnosed with gestational diabetes mellitus (GDM), she will be treated with either diet, medication (i.e., insulin), or both. The most important factor in GDM management is glycemic control to reduce adverse outcomes. Blood glucose levels have become the "key player" for monitoring and directing treatment during pregnancy. Large trials have confirmed that treatment of GDM to optimize glycemic control can decrease the incidence of many of these associated adverse maternal and neonatal outcomes. Up to now, SMBG (self-monitoring of blood glucose) is recommended for women with gestational diabetes that involves finger pricking up to six times daily. However, SMBG provides an incomplete picture of the daily glucose profile due to long intervals between finger pricking, and inaccurate self-reported measurements, which heavily rely on patients' compliance.
Looking for future studies?
Notify Me18 year–45 year
Female
Interventional
Not applicable
Bern, 3010, Switzerland
The incidence of obesity and diabetes is rising worldwide even in younger populations. With a rise in maternal obesity also gestational diabetes mellitus (GDM) becomes more prevalent with a prevalence of up to 18% of pregnancies. Up to now, SMBG (self-monitoring of blood glucose) is recommended for women with gestational diabetes that involves finger pricking up to six times daily. The main purpose of this study is to prove that real time continuous glucose monitoring (rt-CGM) can effectively reduce the risk for adverse pregnancy and neonatal outcome in GDM. It is further hypothesized that rt-CGM can optimize maternal glycaemic control, increase patients satisfaction and adherence to management strategies of GDM. This is a open label randomized controlled trial with two parallel groups.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Continuous glucose monitoring system
Standard Care
Time frame: 2 years
The primary endpoint is composite adverse pregnancy and neonatal outcome; the proportion of large for gestation age (LGA) newborns (birth weight >90th centile); fetal macrosomia (estimated fetal weight over the 95th centile); incidence of polyhydramnios (maximal vertical pocket ≥ 8 cm); rate of neonatal hypoglycaemia; occurrence of stillbirth. Every each and one of these variables contributes to a better neonatal outcome and are associated. This composite endpoint includes factors influencing decisive the neonatal outcome.
Time frame: 10-14 weeks
Need for antiglycemic therapy in example Insulin yes/no
Time frame: 10-14 weeks
Glycemic variability including number and duration of hypoglycemic and hyperglycemic events, mean interstitial glucose in mmol/L and its standard deviation (SD) A hypoglycemic event was defined for two separate analyses as excursions of at least 15 min below the target range (<3.5 mmol/L), and a hyperglycemic event was defined for two separate analyses as excursions of at least 15 min above the target range (>7.8 mmol/L).
Time frame: 10-14 weeks
Time in glucose target in %
Time frame: 10-14 weeks
Duration and frequency postprandial hyperglycaemic excursions
Time frame: 10-14 weeks
Hemoglobin A1c (HbA1c) values (at inclusion, birth and postpartum) in %
Time frame: 10-14 weeks
Pregnancy Complications such as
Time frame: 10-14 weeks
Mode of delivery including cesarean delivery, induction of labor, need for operative vaginal delivery (forceps or vacuum-assisted vaginal delivery)
Time frame: 10-14 weeks
Induction of labor yes/no
Time frame: 10-14 weeks
Obstetric injury yes/no
Time frame: 10-14 weeks
Body mass index (BMI) (pre-pregnancy and at the time of delivery) weight and height will be combined to report BMI in kg/m^2
Time frame: 10-14 weeks
Weight gain after GDM diagnosis in kg
Time frame: 10-14 weeks
Adherence to therapy yes/no
Time frame: 10-14 weeks
Patient satisfaction after pregnancy evaluated through a questionnaire
Time frame: 10-14 weeks
8 weeks postpartum oral glucose test values in mmol/L
Time frame: 10-14 weeks
Gestational age at delivery in weeks
Time frame: 10-14 weeks
Preterm delivery (delivery < 37 weeks gestational age) yes/no
Time frame: 10-14 weeks
Birth weight in grams
Time frame: 10-14 weeks
Small for gestational age (birth weight < 10%) yes/no
Time frame: 10-14 weeks
Poor condition at birth (Apgar score at 5 minutes <7, Arterial pH of <7.0) yes/no
Time frame: 10-14 weeks
Perinatal morbidity prior to hospital discharge.
Time frame: 10-14 weeks
Birth trauma (brachial plexus injury, or clavicular, humeral, or skull fracture)
Time frame: 10-14 weeks
Need for resuscitation yes/no
Time frame: 10-14 weeks
Admission to neonatal intensive care unit (NICU) with length of stay in days
Time frame: 10-14 weeks
Respiratory distress syndrome (need for supplemental oxygen > 4 hours after birth) yes/no
Insel Gruppe AG, University Hospital Bern
Other
Diabetes in Pregnancy Project Und Mobile Health in Gestational Diabetes: An Open Label Randomized Controlled Monocentric Trial on the Utility of Real Time Continuous Glucose Monitoring in the Care of Gestational Diabetes Versus Standard Care
Acronym: DiP GlucoMo
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07336914
Diabetes Mellitus, Diabetes, Gestational
Peshawar, Khyber Pakhtunkhwa, Pakistan
View Trial DetailsNCT06127823
Diabetes Mellitus, Diabetes, Gestational
Herlev, Denmark
View Trial DetailsNCT04724330
Body Weight, Body Weight Changes
Baltimore, Maryland, United States
View Trial DetailsNCT06556927
Anxiety, Anxiety Disorders
Kırklareli, Turkey (Türkiye)
View Trial Details